Breakthrough treatment may end insulin use in type 2 diabetic patients
HQ Team October 15, 2024: A recent study presented at the United European Gastroenterology Week congress in Vienna unveiled a procedure that could.
Bharti Rana Jayshankar – Founder
She brings in more than 30 years of experience in content building, architecture, writing, editing and storytelling. Ms Jayshankar has worked in the Economic Times daily, IBT Times, Investopedia and more than a dozen content firms as a content strategist and planner.
Jay Shankar – Co-founder
He has almost three decades of experience in journalism. He has worked with national dailies such as ET, Indian Express, The Pioneer, The Hindu, Agence France Presse and Bloomberg.
HQ Team October 15, 2024: A recent study presented at the United European Gastroenterology Week congress in Vienna unveiled a procedure that could.
HQ Team October 15, 2024: Severe sepsis and septic shock are major causes of mortality in intensive care unit (ICU) patients. According to.
HQ Team October 14, 2024: Children with aggressive blood cancer may soon have access to a new treatment, CAR T-cell therapy, targeting T-cell.
US-based Baxter International Inc., is implementing an allocation policy to limit stockpiling of its drugs after Hurricane Helene ripped through its facility in.
Dengue cases in the Americas Region exceeded the number of cases historically reported in a year, as compared to all previously recorded years,.
HQ Team October 8, 2024:Humanity is hitting the upper limit of life expectancy, according to a new study. Medical advances have led to.
Johnson and Johnson discontinued a study of an investigational drug to treat bladder cancer after it failed to yield desired results
HQ Team October 7, 2024: Rheumatoid arthritis (RA), an autoimmune disease that causes joint and bone inflammation, is affected by gut bacteria. Researchers.
UK-based DIOSynVax, a biotechnology company, has developed a single candidate vaccine neutralizing immune responses across the spectrum of very diverse H5 subtypes of influenza.
British-Swedish AstraZeneca signed a $1.92 billion licensing agreement with CSPC Pharmaceutical Group to develop, manufacture and commercialize a compound to treat a metabolic.